DCTH stock icon

Delcath Systems
DCTH

$8.31
0.97%
 

About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Employees: 76

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

260% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $332K

200% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]

41% more capital invested

Capital invested by funds: $28.3M [Q4 2023] → $39.9M (+$11.6M) [Q1 2024]

3.32% more ownership

Funds ownership: 30.9% [Q4 2023] → 34.22% (+3.32%) [Q1 2024]

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

14% less funds holding

Funds holding: 42 [Q4 2023] → 36 (-6) [Q1 2024]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$20
141%
upside
Avg. target
$22
169%
upside
High target
$25
201%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
165%upside
$22
Buy
Maintained
15 May 2024
Stephens & Co.
Sudan Loganathan
201%upside
$25
Overweight
Initiated
14 May 2024
HC Wainwright & Co.
Swayampakula Ramakanth
141%upside
$20
Buy
Maintained
27 Mar 2024

Financial journalist opinion

Based on 3 articles about DCTH published over the past 30 days